Mr. Rene Goehrum reports

BIOSYENT RELEASES FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2023

BioSyent Inc. has released its financial results for the fourth quarter and full year ended Dec. 31, 2023. Key highlights are shown in the attached table.

• Return on Equity for FY 2023 was 19% as compared to 17% for FY 2022
• During FY 2023, repurchased for cancellation a total of 400,100 common shares under a Normal Course Issuer Bid (NCIB)
• Paid quarterly dividends of $0.04 per common share on March 15, 2023, June 15, 2023, September 15, 2023, December 15, 2023 and declared subsequent quarterly dividend of $0.045 per common share to be paid on March 15, 2024

"We reported our highest ever Canadian pharmaceutical sales in Q4 2023 with 10% growth over the prior period, driven by our established products," commented Mr. Rene Goehrum, President and CEO of BioSyent. During Q4 2023, we also commenced distribution of the new Gelclair(TM) oncology supportive care product in Canada. Gelclair(TM) was our third new product launch in Canada in 2023, preceded by Inofolic(TM) in the third quarter, and FeraMAX(TM) Pd Maintenance 45 in the first quarter. Although we incurred incremental selling and marketing expenses associated with these three launch products during 2023, our net profit margin of 20% for the year was consistent with 2022. As we continued to execute and invest in our strategic priorities of profitable long-term growth and product portfolio diversification during 2023, we are also proud to have concurrently returned nearly $5 million in capital to our shareholders during the year through both regular quarterly dividends and ongoing share buybacks. I look forward to reporting on our continued progress towards our strategic priorities during 2024."

The CEO's presentation on the Q4 and FY 2023 Results is available on the company's website.

The Company's Audited Consolidated Financial Statements and Management's Discussion and Analysis for the years ended December 31, 2023 and 2022 will be posted on SEDAR+ on March 13, 2024.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the Company has 11,612,179 common shares outstanding.

We seek Safe Harbor.